Jounce Therapeutics Stock Is Trading After $25M In Milestone Payment From Gilead
The FDA has signed off Jounce Therapeutics Inc’s (NASDAQ:JNCE) Investigational New Drug (IND) application for JTX-1811, triggering a milestone payment of…
Jounce Therapeutics Says Achieves First Milestone IIn Exclusive License Agreement With Gilead Sciences, FDA Clearance Of Investigational New Drug Application For Anti-CCR8 Antibody
Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the U.S. Food and Drug
Jounce Therapeutics Presents Trial in Progress Posters on the INNATE and SELECT Clinical Trials at the 2021 American Society of Clinical Oncology Virtual Annual Meeting
- INNATE trial to include proof-of-concept expansion cohorts in lung, renal, head and neck, triple negative breast, cutaneous squamous cell, and ovarian cancers and soft tissue sarcomas -
- SELECT TISvopra positivity
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-specific news flow dictated stock moves during the week.
Earnings Scheduled For May 4, 2021
Companies Reporting Before The Bell
• Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million.
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.